Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Elizabeth K. Lee; Zhenying Tan-Wasielewski; Carol Aghajanian; Robert L. Coleman; Jennifer Curtis; Michelle S. Hirsch; Ursula A. Matulonis; Lewis C. Cantley; Gordon B. Mills; L. Austin Doyle; Joyce F. Liu

Gynecologic Oncology Reports (May 2020)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Elizabeth K. Lee,
Zhenying Tan-Wasielewski,
Carol Aghajanian,
Robert L. Coleman,
Jennifer Curtis,
Michelle S. Hirsch,
Ursula A. Matulonis,
Lewis C. Cantley,
Gordon B. Mills,
L. Austin Doyle,
Joyce F. Liu

Affiliations

Elizabeth K. Lee: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
Zhenying Tan-Wasielewski: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, United States
Carol Aghajanian: Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States
Robert L. Coleman: Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Jennifer Curtis: Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
Michelle S. Hirsch: Department of Pathology, Women’s and Perinatal Division, Brigham and Women’s Hospital, Boston, MA, United States
Ursula A. Matulonis: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
Lewis C. Cantley: Meyer Cancer Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, United States
Gordon B. Mills: Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
L. Austin Doyle: Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States
Joyce F. Liu: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States; Corresponding author at: Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, United States.

Journal volume & issue: Vol. 32

Abstract

Read online

Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.

Published in Gynecologic Oncology Reports

ISSN: 2352-5789 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Gynecology and obstetrics; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/gynecologic-oncology-reports/

About the journal

Abstract

Keywords